Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)
ID: 355991Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355991

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-024.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)" aimed at establishing infrastructure for early-phase cancer prevention clinical trials. This initiative seeks to conduct trials that evaluate the safety and effectiveness of various preventive agents while also characterizing their molecular impacts, with a focus on recruiting participants from high-risk populations for diverse cancer types. The program anticipates funding of $8.75 million annually over six years for five awardees, emphasizing collaboration among various institutions, including higher education and nonprofit organizations. Interested applicants can find more details and application instructions at the provided link, with a submission deadline of October 31, 2024.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-24-024-Full-Announcement.html
    RFA-CA-24-024.html
    The National Institutes of Health (NIH) is supporting the Cancer Prevention Clinical Trials Network (CP-CTNet) through a funding opportunity (RFA-CA-24-024) aimed at conducting early phase clinical trials focused on cancer prevention. The initiative's primary objectives include designing and executing trials to evaluate the safety and effectiveness of various preventive agents, alongside the molecular characterization of their impacts. CP-CTNet will consist of multiple sites, each led by a Lead Academic Organization (LAO), with a companion funding opportunity for a Data Management, Auditing, and Statistical Center. The program emphasizes collaboration among diverse institutions, aiming to recruit participants from high-risk populations for trials related to various cancers, including less common forms. The anticipated funding is $8.75 million annually over six years for five awardees, allowing for innovative trial designs and comprehensive biomarker analyses. Institutions eligible to apply include higher education and nonprofit organizations, with a focus on integrating diverse participation. The document lays out comprehensive application instructions, review criteria, and program expectations, highlighting the NIH's commitment to advancing public health through targeted cancer prevention research initiatives.
    Similar Opportunities
    Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Statistical Center (DMASC) (UG1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Cancer Prevention Clinical Trials Network (CP-CTNet) to establish a Data Management, Auditing, and Statistical Center (DMASC) through a cooperative agreement. This initiative aims to support the design and execution of early-phase clinical trials focused on cancer prevention strategies, assessing the safety, tolerability, and efficacy of various interventions while enhancing operational efficiencies and data integration across the network. The DMASC will play a crucial role in providing centralized data management, auditing clinical trial processes, and offering statistical support, ultimately addressing significant public health challenges related to cancer prevention. The project is set for a six-year period with an annual funding commitment of $3,250,000, and interested applicants must submit their proposals by October 31, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network (NCTN) - Network Group Operations Centers, which will require a U10 clinical trial. This initiative aims to provide scientific leadership for the development and implementation of multi-disciplinary, multi-institutional clinical trials targeting various cancer types and populations, focusing on late-phase treatment trials and advanced imaging studies. The funding, estimated at $99.3 million, is intended to support the conduct of essential clinical research for adults, adolescents, and children with cancer, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, applicants should prepare their submissions in advance of the anticipated award date of March 1, 2026.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at enhancing clinical trials focused on cancer prevention and control. This program seeks to address critical gaps in knowledge regarding study populations, interventions, and operational challenges, facilitating the collection of essential data to finalize protocols for future clinical trials. The initiative is particularly important for improving cancer-related health behaviors, screening, and the long-term outcomes of cancer survivors. Eligible applicants include a diverse range of organizations, with funding available up to $600,000 over three years, and applications are due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)" aimed at fostering collaborations between institutions serving underserved populations and NCI-designated Cancer Centers. The initiative seeks to enhance cancer research capacity, promote workforce diversity, and implement community outreach initiatives to address cancer health disparities. This program is vital for developing comprehensive research projects that include administrative cores, research education, and outreach efforts, ultimately contributing to a stronger national cancer program. Eligible applicants can request funding of up to $2.2 million over five years, with the application submission period starting on December 15, 2023. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" (UG3/UH3), aimed at accelerating the development of evidence-based cancer interventions that reflect the diversity of the U.S. population. This initiative seeks applications that propose interventions designed to improve cancer-related outcomes through pragmatic trial designs, with a particular focus on addressing health disparities among underrepresented populations. The funding opportunity allows for a total of up to $500,000 annually for the UG3 phase and $750,000 for the UH3 phase, with applications accepted until November 17, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source: NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for a single-source grant aimed at establishing the NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network. This initiative seeks to partner with private institutions of higher education to conduct large-scale, multi-site clinical trials, focusing on late-phase treatment trials and advanced imaging across various cancer types, while ensuring regulatory oversight in Canada. The funding, estimated at $3.8 million, is intended to support the NCTN's efforts to enhance clinical research for diverse patient populations, with the application due in late February 2025 and the award anticipated by March 1, 2026. Interested applicants should prepare their proposals in advance of the expected NOFO publication in Fall 2024.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network, specifically targeting Network Lead Academic Participating Sites through a cooperative agreement. The primary objective is to provide scientific leadership in developing and conducting multi-center clinical trials for various cancer treatments, contributing to substantial patient accrual across the NCTN. This initiative is crucial for advancing clinical research and improving treatment options for diverse patient populations affected by cancer. The estimated total program funding is $35,100,000, with an award ceiling of $1,700,000 and approximately 35 awards expected. Interested applicants should prepare for the anticipated application due date in late February 2025, following the NOFO publication in Fall 2024.